Abstract: The present invention relates to the use of benzazepine-N-acetic acid derivatives which contain an oxo-group in the &agr;-position to the nitrogen atom and are substituted in position 3 by a 1-(carboxyalkyl)cyclo-entylcarbonylamino radical, and their salts and biolabile esters for the treatment of hypertension, particularly for the treatment of certain forms of secondary hypertension, in larger mammals and particularly humans, and for the production of pharmaceutical compositions suitable for this treatment. The cause of the hypertension to be treated may have a wide variety of origins. The invention particularly relates to the treatment of those forms of secondary hypertension which may occur as a result of various non-cardiac diseases.

Abstract: N-triazolylmethyl-piperazine compounds which exhibit neurokinin receptor antagonistic activity corresponding to the formula I: wherein R1, R2 and R3 have the meanings given in the specification; pharmaceutical compositions containing these compounds; a process for preparing these compounds, and intermediate products of this process.

Abstract: The use of moxonidine or a physiologically compatible acid addition salt thereof for the treatment and/or inhibition of functional gastrointestinal disturbances or illnesses in the region of the lower intestinal tracts, particularly for the treatment and/or inhibition of abdominal visceral pain which accompanies them, and the preparation of pharmaceutical compositions suitable for this treatment are is described. The functional disturbances and illnesses of the lower intestinal tracts which can be treated according to the invention are known in particular as irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD), which generally also include visceral pain as one of their symptoms.

Abstract: A pharmaceutical analgesic composition comprise an opioid analgesic agent and moxonidine as a non-opioid agent with analgesic activity. Administration of an opioid analgesic agent and moxonidine as a non-opioid agent produces analgesia in the treatment of pain in mammals.

Abstract: The invention relates to a device or equipment as well as to a method for the simultaneous, fractionating operation of a plurality of parallel chromatographic columns. It is particularly advantageous to apply this equipment and method in research, in the framework of organic synthesis for simultaneous, parallel separation, isolation and purification of a plurality of chemical compounds, e.g. of potential new active ingredients for medicaments, particularly also on the semi-preparative scale.

Abstract: A door assembly for a sterile or safe room has a door leaf mounted in the door frame by hinge plates and a hose-type seal along the edge of the door leaf edge, when inflated presses against a smooth surface of the frame juxtaposed with the edge of the leaf. The seal is resilient so that it restores to its uninflated position releasing the lock in one to six seconds.

Abstract: Ring-contracted N-demethyl-N-isopropyl-erythromycin-A derivatives having a modified side chain and gastrointestinally effective motilin-agonistic properties and the preparation thereof are described.

Abstract: Moxonidine and its physiologically compatible acid-addition salts are used for the treatment and/or prophylaxis of nociceptive pain, and in particular nociceptive acute and chronic pain.

Abstract: The use of moxonidine an its physiologically compatible acid-addition salts for the treatment and/or prophylaxis of disorders of thermogenesis and for the stimulation of thermogenesis in persons with abnormally reduced energy turnover and/or persons with reduced thermogenesis during or following a weight loss diet is disclosed.

Abstract: A method of relieving neuropathic pain uses moxonidine and its physiologically compatible acid-addition salts for the treatment and/or prophylaxis of neuropathic pain. A composition comprising an effective amount of moxonidine, or a pharmaceutically acceptable salt thereof, in a pharmaceutically acceptable carrier, is administered to a subject in need of such treatment. The composition may be administered intrathecally.

Abstract: Neurokinin-antagonistic compounds corresponding to formula I: ##STR1## in which R.sup.1 is hydrogen or lower alkyl,R.sup.2 is hydrogen, lower alkyl, lower alkoxy, halogen or trifluoromethyl, andR.sup.3 is hydrogen, lower alkyl, lower alkoxy, halogen or trifluoromethyl, orR.sup.2 and R.sup.3 together are alkylenedioxy with 1 to 2 carbon atoms, bonded to adjacent carbon atoms of the phenyl ring,R.sup.4 is hydrogen, lower alkyl, lower alkoxy, halogen or trifluoromethyl, andR.sup.5 is hydrogen, lower alkyl, lower alkoxy, halogen or trifluoromethyl, orR.sup.4 and R.sup.5 together are alkylenedioxy with 1 to 2 carbon atoms, bonded to adjacent carbon atoms of the phenyl ring,R.sup.6 is lower alkyl, halogen or trifluoromethyl,R.sup.7 is lower alkyl, halogen or trifluoromethyl,A is a --(CH.sub.2).sub.n -- group in which n represents an integer from 1 to 3, or an --NH--(CH.sub.2).sub.

Abstract: Compounds of Formula I ##STR1## wherein R.sup.1 is hydrogen or lower alkyl,R.sup.2 is hydrogen or halogen andR.sup.3 is hydrogen or lower alkoxy,and their pharmacologically acceptable acid addition salts and pharmaceutical compositions containing these compounds and also processes for the preparation of these compounds. Pharmaceutical composition containing these compounds are suitable, for example, for treating functional and inflammatory disorders of the gastrointestinal tract.

Abstract: The use of complex lipids, especially lecithin, as additives to stabilize water-soluble pharmaceutical preparations of digestive enzyme mixtures containing lipases and proteases, especially pancreatin-containing digestive enzyme mixtures, which are suitable for preparing aqueous solutions for continuous introduction into the gastrointestinal tract by means of a tube, against a decrease in lipolytic activity under the influence of moisture.

Abstract: Solid and liquid pharmaceutical preparations containing cilansetron or its acid addition salts as active substance which include an amount sufficient to stabilize cilansetron against racemization, of a physiologically compatible water-soluble acid additive selected from monobasic or multibasic organic acids having 2 to 12 carbon atoms with a first p.sub.s value between 1.1 and 4.8, acid salts of the aforementioned multibasic organic acids, and acid salts of multibasic mineral acids having a first available pK.sub.s value between 1.5 and 7.5, as well as the use of such acid additives for stabilizing cilansetron against racemization in pharmaceutical preparations.

Abstract: A method of using moxonidine or a physiologically acceptable acid addition salt thereof for the treatment and/or prophylaxis of glucose metabolism disorders such as insulin resistance and/or glucose intolerance, and pharmaceutical compositions for use therein.

Abstract: Compounds having NEP-inhibitory activity, corresponding to the formula I in whichR.sup.1 is hydrogen or a group forming a biolabile phosphonic acid ester,R.sup.2 is hydrogen or a group forming a biolabile phosphonic acid ester andR.sup.3 is hydrogen or a group forming a biolabile carboxylic acid esterand physiologically acceptable salts of acids of formula I, and pharmaceutical compositions comprising these compounds.

Abstract: The use of sub-antihypertensive doses of moxonidine or a physiologically compatible acid addition salt thereof for inhibiting renal failure, independent of a reduction in blood pressure, and/or for the preparation of pharmaceutical preparations for the treatment and/or prophylaxis, independent of a reduction in blood pressure, of renal failure.

Abstract: Ring-contracted N-demethyl-N-isopropyl-erythromycin-A-spiroacetal compounds corresponding to formula I ##STR1## having gastrointestinally effective motilin-agonistic properties and the preparation thereof.

Abstract: Compounds having fibrinogen receptor-antagonistic activity, of the general formula I ##STR1## in which Z is oxygen or a methylene group,B is a phenyl or pyridyl radical,R.sup.1 is hydrogen or a group forming a biolabile ester, and their physiologically acceptable acid addition salts and physiologically acceptable salts of acids of formula I.

Abstract: The use is described of compounds of the general formula I ##STR1## wherein R.sup.1 represents a phenyl-lower alkyl group which can optionally be substituted in the phenyl ring by lower alkyl, lower alkoxy or halogen, or represents a naphthyl-lower alkyl group,R.sup.2 denotes hydrogen or a biolabile ester-forming group, andR.sup.3 denotes hydrogen or a biolabile ester-forming group,and physiologically acceptable salts of the acids of formula I for preparing pharmaceutical compositions for the treatment and/or prophylaxis of gastrointestinal blood circulation disturbances.